South and Central America Kidney Disease Market to Grow at a CAGR of 5.9% to reach US$ 9,060.9 Million from 2020 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. South and Central America Kidney Disease Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. South and Central America Kidney Disease Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Favorable Reimbursement Policy for Kidney Disease Treatments
5.1.2 High Prevalence of Chronic Diseases Leading to Kidney Diseases

5.2 Market Opportunities

5.2.1 Increase in Preference for Robotic Surgeries for Kidney Diseases

5.3 Future Trends

5.3.1 Rise in Preference for Advanced Hemodialysis Therapies

5.4 Impact of Drivers and Restraints

6. South and Central America Kidney Disease Market Regional Analysis

6.1 South and Central America Kidney Disease Market Overview

6.2 South and Central America Kidney Disease Market Revenue 2017-2027 (US$ Million)

6.3 South and Central America Kidney Disease Market Forecast Analysis

7. South and Central America Kidney Disease Market Analysis – by Product

7.1 Diagnosis and Treatment

7.1.1 Overview
7.1.2 Diagnosis and Treatment: South and Central America Kidney Disease Market – Revenue and Forecast to 2031 (US$ Million)

8. South and Central America Kidney Disease Market Analysis – by End User

8.1 Hospitals

8.1.1 Overview
8.1.2 Hospitals: South and Central America Kidney Disease Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Diagnostic Laboratories

8.2.1 Overview
8.2.2 Diagnostic Laboratories: South and Central America Kidney Disease Market – Revenue and Forecast to 2027 (US$ Million)

9. South and Central America Kidney Disease Market – South and Central America Analysis

9.1 South and Central America

9.1.1 South and Central America Kidney Disease Market Breakdown, by Key Country, 2020 and 2027 (%)
9.1.1.1 South and Central America Kidney Disease Market – Revenue and Forecast Analysis – by Country
9.1.1.1 Brazil: South and Central America Kidney Disease Market – Revenue and Forecast to 2027 (US$ Million)

9.1.1.1.1 Brazil: South and Central America Kidney Disease Market Breakdown, by Product
9.1.1.1.2 Brazil: South and Central America Kidney Disease Market Breakdown, by End User

9.1.1.2 Argentina: South and Central America Kidney Disease Market – Revenue and Forecast to 2027 (US$ Million)

9.1.1.2.1 Argentina: South and Central America Kidney Disease Market Breakdown, by Product
9.1.1.2.2 Argentina: South and Central America Kidney Disease Market Breakdown, by End User

9.1.1.3 Rest of South and Central America : South and Central America Kidney Disease Market – Revenue and Forecast to 2027 (US$ Million)

9.1.1.3.1 Rest of South and Central America : South and Central America Kidney Disease Market Breakdown, by Product
9.1.1.3.2 Rest of South and Central America : South and Central America Kidney Disease Market Breakdown, by End User

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. South and Central America Kidney Disease Market Industry Landscape

11.1 Overview

11.2 Mergers and Acquisitions

11.3 Agreements, Collaborations, and Joint Ventures

11.4 New Product Launches

11.5 Expansions and Other Strategic Developments

12. Company Profiles

12.1 Abbott

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 F. Hoffmann-La Roche Ltd

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 AbbVie Inc.

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 Pfizer Inc.

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Teva Pharmaceutical Industries Ltd

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 GlaxoSmithKline plc.

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

12.7 Sysmex Corporation

12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

12.8 Siemens AG

12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments

12.9 Amgen Inc.

12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments

13. Appendix

13.1 About Business Market Insights